Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HGFAC | Q04756 | 5/20 | 0.97 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.73 |
| ▸ | F2 | P00734 | 4/20 | 0.73 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.73 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.73 |
| ▸ | ACR | P10323 | 8/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | PLAU | P00749 | 1/20 | 0.65 |
| ▸ | PLG | P00747 | 1/20 | 0.64 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358345 | 0.99 | HGFAC (1.00) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL10636579 | 0.84 | KMT2A (0.84) | HGFACPKMKMT2A | |
| SCHEMBL542043 | 0.84 | KMT2A (0.84) | HGFACPKMKMT2A | |
| SCHEMBL4951809 | 0.84 | KMT2A (0.84) | HGFACPKMKMT2A | |
| SCHEMBL18434657 | 0.84 | KMT2A (0.84) | HGFACPKMKMT2A | |
| Hydrochloric Acid SCHEMBL7258089 | 0.82 | PLAU (0.96) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL240459 | 0.81 | PLAU (1.00) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL29029504 | 0.80 | KMT2A (1.00) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL27462144 | 0.80 | HGFAC (0.67) | HGFACPRSS1F2PRSS2PRSS3 | |
| SCHEMBL12489991 | 0.79 | PKM (0.77) | HGFACPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090644-A1 | E. COLI EXPRESSED RECOMBINANT HUMAN MICROPLASMIN, A PRODUCTION METHOD THEREOF, A PHARMACEUTICAL COMPOSITION AND A KIT COMPRISING THEREOF, A METHOD AND AN APPLICATION OF TREATING THROMBOEMBOLISM RELATED DISEASES BY USING THEREOF | Shenzhen Bay Laboratory (CN) | 2025-03-20 | — | — | US | disclosed |
| EP-4511113-A1 | A SHORT IN VIVO HALF-LIFE AND IN VIVO UNSTABLE RECOMBINANT MICROPLASMIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND METHOD OF TREATING THROMBOEMBOLISM RELATED DISEASES INCLUDING ADMINISTRATION THEREOF | Shenzhen Bay Laboratory (CN) | 2025-02-26 | — | — | EP | disclosed |
| EP-4496888-A1 | AN E. COLI EXPRESSED RECOMBINANT HUMAN MICROPLASMIN, A PRODUCTION METHOD THEREOF, A PHARMACEUTICAL COMPOSITION AND A KIT COMPRISING THEREOF, A METHOD AND AN APPLICATION OF TREATING THROMBOEMBOLISM RELATED DISEASES BY USING THEREOF | Shenzhen Bay Laboratory (CN) | 2025-01-29 | — | — | EP | disclosed |
| CN-119053700-A | Recombinant human microfibrillatase expressed by escherichia coli, production method thereof, pharmaceutical composition containing recombinant human microfibrillatase and kit, and method for treating thromboembolism-related diseases by using recombinant human microfibrillatase | 深圳湾实验室 | 2024-11-29 | — | — | CN | disclosed |
| US-11964004-B2 | Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof | Shenzhen Bay Laboratory (CN) | 2024-04-23 | — | — | US | disclosed |
| CN-116867511-A | Recombinant microfibrillated enzyme having short in vivo half-life and being unstable in vivo, pharmaceutical composition comprising the same and method for treating thromboembolic related diseases comprising administering the same | 深圳湾实验室 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023185918-A1 | AN E. coli EXPRESSED RECOMBINANT HUMAN MICROPLASMIN, A PRODUCTION METHOD THEREOF, A PHARMACEUTICAL COMPOSITION AND A KIT COMPRISING THEREOF, A METHOD AND AN APPLICATION OF TREATING THROMBOEMBOLISM RELATED DISEASES BY USING THEREOF | Shenzhen Bay Laboratory (CN) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023185188-A1 | A SHORT IN VIVO HALF-LIFE AND IN VIVO UNSTABLE RECOMBINANT MICROPLASMIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND METHOD OF TREATING THROMBOEMBOLISM RELATED DISEASES INCLUDING ADMINISTRATION THEREOF | Shenzhen Bay Laboratory (CN) | 2023-10-05 | — | — | WO | disclosed |
| US-20220387564-A1 | SHORT IN VIVO HALF-LIFE AND IN VIVO UNSTABLE RECOMBINANT MICROPLASMIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND METHOD OF TREATING THROMBOEMBOLISM RELATED DISEASES INCLUDING ADMINISTRATION THEREOF | Shenzhen Bay Laboratory (CN) | 2022-12-08 | — | — | US | disclosed |